Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 13, 2013, Pages 4968-4973

  Liang, Yuh Jin ^a,b,c   Ding, Yao ^a,b   Levery, Steven B ^d   Lobaton, Marlin ^a   Handa, Kazuko ^a   Hakomori, Sen Itiroh ^a,b  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GD 1A; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; MESSENGER RNA; MONOSIALOGANGLIOSIDE; TRANSCRIPTION FACTOR TWIST;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER STEM CELL; CELL MOTILITY; CELL POPULATION; CELL STRUCTURE; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DOWN REGULATION; ELECTROSPRAY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE SILENCING; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 84875530777     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1302825110     Document Type: Article

References (69)

1. Handa K, Hakomori SI (2012) Carbohydrate to carbohydrate interaction in development process and cancer progression. Glycoconj J 29(8-9):627-637.
2. Hakomori SI (2010) Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett 584(9):1901-1906.
3. International Union of Pure and Applied Chemistry and International Union of Biochemistry Commission on Biochemical Nomenclature (1977) The nomenclature of lipids. Recommendations 1976. Lipids 12(6):455-468.
4. Svennerholm L (1964) The Gangliosides. J Lipid Res 5:145-155.
5. Hakomori SI, Murakami WT (1968) Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc Natl Acad Sci USA 59(1):254-261.
6. Mora PT, Brady RO, Bradley RM, McFarland VW (1969) Gangliosides in DNA virustransformed and spontaneously transformed tumorigenic mouse cell lines. Proc Natl Acad Sci USA 63(4):1290-1296.
7. Miljan EA, Bremer EG (2002) Regulation of growth factor receptors by gangliosides. Sci STKE 160:re15.
8. Miljan EA, et al. (2002) Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem 277(12):10108-10113.
9. Buck CA, Glick MC, Warren L (1971) Effect of growth on the glycoproteins from the surface of control and Rous sarcoma virus transformed hamster cells. Biochemistry 10(11):2176-2180.
10. Ogata SI, Muramatsu T, Kobata A (1976) New structural characteristic of the large glycopeptides from transformed cells. Nature 259(5544):580-582.
11. Lennarz WJ (1980) The Biochemistry of Glycoproteins and Proteoglycans (Plenum, New York).
12. Narimatsu H, Sinha S, Brew K, Okayama H, Qasba PK (1986) Cloning and sequencing of cDNA of bovine N-acetylglucosamine (beta 1-4) galactosyltransferase. Proc Natl Acad Sci USA 83(13):4720-4724.
13. Shaper NL, et al. (1986) The human galactosyltransferase gene is on chromosome 9 at band p13. Somat Cell Mol Genet 12(6):633-636.
14. Miura Y, et al. (2004) Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc Natl Acad Sci USA 101(46):16204-16209.
15. Nishihara S, et al. (1994) Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem 269(46):29271-29278.
16. Iwai T, et al. (2005) Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci USA 102(12):4572-4577.
17. Sugrue SP, Hay ED (1981) Response of basal epithelial cell surface and cytoskeleton to solubilized extracellular matrix molecules. J Cell Biol 91(1):45-54.
18. Greenburg G, Hay ED (1982) Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 95(1):333-339.
19. Hay ED (2005) The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 233(3):706-720.
20. Turley EA, Veiseh M, Radisky DC, Bissell MJ (2008) Mechanisms of disease: Epithelial-mesenchymal transition-Does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 5(5):280-290.
21. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890.
22. Guan F, Handa K, Hakomori SI (2009) Specific glycosphingolipids mediate epithelialto-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA 106(18):7461-7466.
23. Guan F, Schaffer L, Handa K, Hakomori SI (2010) Functional role of gangliote-traosylceramide in epithelial-to-mesenchymal transition process induced by hypoxia and by TGF-beta. FASEB J 24(12):4889-4903.
24. Fenderson BA, Andrews PW, Nudelman E, Clausen H, Hakomori SI (1987) Glycolipid core structure switching from globo- to lacto- and ganglio-series during retinoic acidinduced differentiation of TERA-2-derived human embryonal carcinoma cells. Dev Biol 122(1):21-34.
25. Liang YJ, et al. (2011) Changes in glycosphingolipid composition during differentiation of human embryonic stem cells to ectodermal or endodermal lineages. Stem Cells 29(12):1995-2004.
26. Liang YJ, et al. (2010) Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation. Proc Natl Acad Sci USA 107(52):22564-22569.
27. Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: An evolving concept. Nat Rev Cancer 12(2):133-143.
28. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730-737.
29. Uchida N, et al. (2000) Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97(26):14720-14725.
30. Dalerba P, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104(24):10158-10163.
31. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983-3988.
32. Terris B, Cavard C, Perret C (2010) EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 52(2):280-281.
33. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5(4):275-284.
34. Creighton CJ, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33): 13820-13825.
35. Li X, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672-679.
36. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24):1777-1785.
37. Zhang M, Atkinson RL, Rosen JM (2010) Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci USA 107(8):3522-3527.
38. Ponti D, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65(13):5506-5511.
39. Sheridan C, et al. (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59.
40. Ricardo S, et al. (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol 64(11):937-946.
41. Johnston MD, Maini PK, Jonathan Chapman S, Edwards CM, Bodmer WF (2010) On the proportion of cancer stem cells in a tumour. J Theor Biol 266(4):708-711.
42. Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease: Old views and new perspectives. Int J Dev Biol 53(8-10):1541-1547.
43. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA (2009) Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 119(6):1438-1449.
44. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704-715.
45. Morel AP, et al. (2008) Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoS ONE 3(8):e2888.
46. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF (2010) Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 107(8):3722-3727.
47. Lapidot T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645-648.
48. Dick JE (2003) Breast cancer stem cells revealed. Proc Natl Acad Sci USA 100(7): 3547-3549.
49. Elenbaas B, et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15(1):50-65.
50. Sun H, et al. (2013) CD44(+)/CD24 (-) breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. Clin Transl Oncol 15(1):46-54.
51. Cariati M, et al. (2008) Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122(2): 298-304.
52. Dontu G, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17(10):1253-1270.
53. Charafe-Jauffret E, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4): 1302-1313.
54. Yamaji T, Nishikawa K, Hanada K (2010) Transmembrane BAX inhibitor motif containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 synthase, and reduces Gb3 biosynthesis. J Biol Chem 285(46):35505-35518.
55. Schmitt F, Ricardo S, Vieira AF, Dionísio MR, Paredes J (2012) Cancer stem cell markers in breast neoplasias: Their relevance and distribution in distinct molecular subtypes. Virchows Arch 460(6):545-553.
56. Battula VL, et al. (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122(6):2066-2078.
57. Webb TJ, et al. (2012) Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res 72(15):3744-3752.
58. Becker R, Eichler MK, Jennemann R, Bertalanffy H (2002) Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate. Br J Neurosurg 16(3):269-275.
59. Shibuya H, et al. (2012) Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci 103(9):1656-1664.
60. Hakomori SI (1993) Structure and function of sphingoglycolipids in transmembrane signalling and cell-cell interactions. Biochem Soc Trans 21(3):583-595.
61. Scursoni AM, et al. (2011) Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: An attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011:245181.
62. Chantada GL, et al. (2006) An aggressive bone marrow evaluation including immunocytology with GD2 for advanced retinoblastoma. J Pediatr Hematol Oncol 28(6): 369-373.
63. Masamune H, Yosizawa Z, Oh-Uti K, Matuda Y, Masudawa A (1952) Biochemical studies on carbohydrates. CLVI. On the sugar components of the hexosamine-containing carbohydrates from gastric cancers, normal human gastric mucosa and human liver and of the glacial acetic acid-soluble proteins from those tissues as well as a metastasis in liver of gastric cancer. Tohoku J Exp Med 56(1-2):37-42.
64. Dahr W, Uhlenbruck G, Bird GWG (1974) Cryptic A-like receptor sites in human erythrocyte glycoproteins: proposed nature of Tn-antigen. Vox Sang 27(1):29-42.
65. Hirohashi S, Clausen H, Yamada T, Shimosato Y, Hakomori SI (1985) Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: Its identification as Tn antigen. Proc Natl Acad Sci USA 82(20):7039-7043.
66. Kjeldsen TB, et al. (1988) Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked associated O-linked sialosyl-2′6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 48:2214-2220.
67. Watanabe M, et al. (1991) In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope. Cancer Res 51(8):2199-2204.
68. Ito H, et al. (1992) Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Le(b)/Le(a) glycosphingolipid, a novel extended type 1 chain antigen. Cancer Res 52(13):3739-3745.
69. Stroud MR, Levery SB, Salyan MEK, Roberts CE, Hakomori SI (1992) Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6). Eur J Biochem 203(3):577-586.